Clinical Trials Logo

Clinical Trial Summary

During the pandemic of the new coronavirus infection COVID-19 in the world community, in the Russian Federation, in particular in the Samara region throughout the pandemic period from the end of 2019, when the first outbreak of a new coronavirus infection occurred in Wuhan (Hubei Province) in the People's Republic of China, the main focus on prevention (development of modern vaccines), diagnosis, treatment and further rehabilitation was done on the adult population. Children acted mainly as carriers of this infection and the manifestation of the disease usually occurred in most cases (not counting children with comorbid conditions) in a mild or latent form. At the moment, after 2 years, we can say that postcovid syndrome also occurs in children, regardless of the severity of the disease.


Clinical Trial Description

. During the pandemic of the new coronavirus infection COVID-19 in the world community, in the Russian Federation, in particular in the Samara region throughout the pandemic period from the end of 2019, when the first outbreak of a new coronavirus infection occurred in Wuhan (Hubei Province) in the People's Republic of China, the main focus on prevention (development of modern vaccines), diagnosis, treatment and further rehabilitation was done on the adult population. Children acted mainly as carriers of this infection and the manifestation of the disease usually occurred in most cases (not counting children with comorbid conditions) in a mild or latent form. At the moment, after 2 years, we can say that postcovid syndrome also occurs in children, regardless of the severity of the disease. Post-COVID syndrome (Post-COVID syndrome, Long COVID) is a long-term symptoms lasting 12 or more weeks. In most cases, it manifests itself as a disorder of autonomic and psychological functions (cognitive impairment), to a lesser extent somatic disorders, prolonged subfebrility. If you look at the world statistics, according to the World Health Organization, from December 2019 to October 2021, the number of sick children was: - from 0 to 5 years (children under one year and younger) - 1,890,756, which is only 2% of all reported cases of COVID-19 in the entire world community. The mortality rate in this group of children was 1,797, or 0.1% of the registered deaths worldwide. - from 5 to 14 years old (older children) - 7,058,748, the indicator has slightly increased and accounts for 7% of all reported cases of COVID-19 in the entire world community. The mortality rate in this group of children is slightly lower, amounting to 1,328, or, as in the previous group, 0.1% of the registered deaths worldwide. - from 15 to 24 years old (older adolescents and young people, as there is a different age group in the world community) - 14,819,320, which is 15% of all reported cases of COVID-19 in the world. Mortality in this group is 7,023, or 0.4% of all registered deaths in the world. The total mortality among children, adolescents and young people aged 0 to 25 years was less than 0.5% of the registered deaths in the world. Worldwide, and in the Russian Federation in particular, in 2022, the incidence of COVID-19, according to WHO, among children has increased sharply against the background of an increase in the incidence of the Omicron strain at a time when most countries have weakened public health and social measures. For example, in the United States, by July 2022, there were 14,003,497 cases of the disease in children, and the children were 18,6% (14 003 497 /75 463 921) of all registered cases, with a total of 18,605 cases per 100,000 children in the population. Worldwide, by July 24, 2022, the proportion of children under the age of 5 and children aged 5 to 14 years was 2.47% and 10.44%, respectively. Adolescents and young people aged 15 to 24 accounted for 13.91% of all cases. Children aged 5 years and younger account for 0.11% of all deaths in the world, while children aged 5 to 14 years account for 0.089%, and adolescents and young people account for 0.37% of all reported deaths in the world. In the Russian Federation, there are no statistics on the incidence of a new coronavirus infection in children, there are separate data by region, but there are no general statistics. In this regard, it can be assumed that a large number of children who have suffered COVID-19 is not taken into account, so it is necessary to investigate the postcovid syndrome not only in children who have suffered a new coronavirus infection with confirmed laboratory data, but also in those who have suffered it asymptomatically or under the guise of a common respiratory infection in order to identify long-term and chronic symptoms COVID-19 in children. Having studied the main biological mechanisms that cause these symptoms, we will be able to identify patients at risk of chronic infection, prevent the development of such conditions and will be able to carry out early rehabilitation of children who have suffered COVID-19. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05817006
Study type Interventional
Source Samara State Medical University
Contact
Status Enrolling by invitation
Phase N/A
Start date April 16, 2023
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05926505 - Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Phase 2/Phase 3
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Completed NCT05552612 - Health-related Quality of Life and Long COVID
Completed NCT05531019 - COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A N/A
Not yet recruiting NCT04949386 - Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. Phase 2
Recruiting NCT06118112 - Living With Long COVID: LONGCOVID-EXPERIENCE
Completed NCT05185674 - Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Enrolling by invitation NCT05965739 - RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms N/A
Enrolling by invitation NCT05965752 - RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms N/A
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT05606211 - Pain in Long COVID-19: The Role of Sleep
Active, not recruiting NCT05713266 - Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
Completed NCT05679505 - Vagus Nerve Stimulation for Post-COVID Syndrome N/A
Completed NCT05601180 - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID. N/A
Not yet recruiting NCT06045338 - Mind Body Intervention for Long COVID N/A
Recruiting NCT06091358 - Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation. N/A
Recruiting NCT05566392 - Longterm Influence of Pediatric Long COVID Syndrome
Recruiting NCT05855369 - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss Phase 2/Phase 3
Recruiting NCT05572346 - Digital App for Telerehabilitation in Respiratory Diseases
Recruiting NCT06316843 - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Phase 2